(Q40417514)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Fabien Zoulim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

7

Christian Trépo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Sandra Carrouée-Durantel

5

object named as

Sandra Carrouée-Durantel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Marie-Noëlle Brunelle

1

object named as

Marie-Noëlle Brunelle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Anne-Carole Jacquard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Christian Pichoud

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Jean-Pierre Villeneuve

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

1391-1398

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15915463%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus: old, new and future approaches to antiviral treatment

12 January 2020

cites work

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Hepatitis B virus resistance to antivirals: clinical implications and management.

1 reference

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

7 January 2021

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

7 January 2021

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

1 reference

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

7 January 2021

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

1 reference

7 January 2021

Antiviral drugs in current clinical use.

1 reference

7 January 2021

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

1 reference

7 January 2021

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus

1 reference

7 January 2021

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

1 reference

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

7 January 2021

Entecavir for the treatment of chronic hepatitis B.

1 reference

7 January 2021

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

1 reference

7 January 2021

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

1 reference

7 January 2021

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

7 January 2021

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

1 reference

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

7 January 2021

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

1 reference

7 January 2021

Multiple functions of capsid protein phosphorylation in duck hepatitis B virus replication

1 reference

7 January 2021

Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity

1 reference

7 January 2021

Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus

1 reference

7 January 2021

1 reference

7 January 2021

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

7 January 2021

Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells

1 reference

7 January 2021

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

1 reference

7 January 2021

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

7 January 2021